Referenced link: https://medicalxpress.com/news/2023-03-potential-strategy-cell-therapy-solid.html
Discuss on https://discu.eu/q/https://medicalxpress.com/news/2023-03-potential-strategy-cell-therapy-solid.html
Originally posted by Phys.org / @physorg_com: http://nitter.platypush.tech/medical_xpress/status/1636091665877172229#m
RT by @physorg_com: Study offers a potential strategy to improve T cell therapy in #solidtumors @pennmedicine @PNASNews https://pnas.org/doi/10.1073/pnas.2218632120 https://medicalxpress.com/news/2023-03-potential-strategy-cell-therapy-solid.html
A new approach that delivers a "one-two punch" to help T cells attack solid tumors is the focus of a preclinical study by researchers from the Perelman School of Medicine at the University of Pennsylvania. The findings, published in the Proceedings of the National Academy of Sciences (PNAS), showed that targeting two regulators that control gene functions related to inflammation led to at least 10 times greater T cell expansion in models, resulting in increased antitumor immune activity and durability.
Referenced link: https://medicalxpress.com/news/2023-03-liquid-biopsy-pediatric-solid-tumors.html
Discuss on https://discu.eu/q/https://medicalxpress.com/news/2023-03-liquid-biopsy-pediatric-solid-tumors.html
Originally posted by Phys.org / @physorg_com: http://nitter.platypush.tech/medical_xpress/status/1631664743638335489#m
RT by @physorg_com: Researchers develop #liquidbiopsy test for pediatric #solidtumors @childrensLA @nresearchnews https://www.nature.com/articles/s41698-023-00357-0 https://medicalxpress.com/news/2023-03-liquid-biopsy-pediatric-solid-tumors.html
Pediatric solid tumors make up approximately 40% of all childhood cancers. While pediatric cancer is rare, children can develop a wide range of tumor types, located in different parts of the body, which can make the differential diagnosis challenging. Investigators at Children's Hospital Los Angeles have developed a liquid biopsy for solid tumors that has the potential to aid in reaching a specific diagnosis when surgery or a tissue biopsy is not feasible. The study findings were published in the journal npj Precision Oncology.
Müller-Tidow and colleagues perform a randomized clinical trial and show that administration of convalescent plasma improves COVID-19 outcome in patients with cancer who are unable to generate an adequate immune response.
Abstract. Clonal hematopoiesis of indeterminate potential (CHIP) is characterized by the expansion of hematopoietic cells harboring leukemia-associated somatic mutations in otherwise healthy people and occurs in at least 10% of adults over 70. It is well established that people with CHIP have increased rates of hematologic malignancy, increased risk of cardiovascular disease (CVD), and worse all-cause mortality compared to those without CHIP. Despite recent advancements in understanding CHIP as it relates to these known outcomes, much remains to be learned about the development and role of CHIP in other disease states. Emerging research has identified high rates of CHIP in patients with solid tumors, driven in part by oncologic therapy, and revealed associations between CHIP and differential outcomes in both solid tumors and other diseases. Recent studies have demonstrated that CHIP can contribute to dysregulated inflammatory signaling in multiple contexts, underscoring the importance of interrogating how CHIP might alter tumor immunology. Here, we review the role of CHIP mutations in clonal expansion of hematopoietic cells, explore the relationship between CHIP and solid tumors, and discuss the potential roles of CHIP in inflammation and solid tumor biology.
Matt Willemsen
cafepharma
Yan Leyfman, MD
Phys.org
halama_immuno
Alex Silver